Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 4/20 | 0.42 |
| ▸ | F10 | P00742 | 9/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27251665 | 1.00 | PCSK9 (0.42) | PCSK9F10CCR6NOS1NOS2 | |
| SCHEMBL30827607 | 0.87 | PCSK9 (0.41) | PCSK9CCR6NOS1NOS2PIM1 | |
| SCHEMBL27251664 | 0.87 | PCSK9 (0.41) | PCSK9CCR6NOS1NOS2PIM1 | |
| SCHEMBL30827671 | 0.86 | PCSK9 (0.41) | PCSK9F10CCR6CCNKCDK12 | |
| SCHEMBL27251572 | 0.86 | PCSK9 (0.41) | PCSK9F10CCR6CCNKCDK12 | |
| SCHEMBL29311895 | 0.86 | CCR6 (0.41) | PCSK9CCR6CCNKCDK12 | |
| SCHEMBL30827612 | 0.86 | CCR6 (0.41) | PCSK9CCR6CCNKCDK12 | |
| SCHEMBL27251465 | 0.85 | PCSK9 (0.55) | PCSK9F10KCNH2 | |
| SCHEMBL30827688 | 0.83 | PCSK9 (0.41) | PCSK9F10MAPK14MAPK8 | |
| SCHEMBL27251557 | 0.83 | PCSK9 (0.41) | PCSK9F10MAPK14MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590397-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| WO-2024062090-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | PCSK9 1/4885F10 102/4885CCR6 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.